A carregar...
Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting
The use of targeted therapeutics known as poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors in the management of ovarian cancer is currently transforming clinical practice. The PARP inhibitor rucaparib is indicated in the UK, European Union and the United States for use in the treatmen...
Na minha lista:
| Publicado no: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7257860/ https://ncbi.nlm.nih.gov/pubmed/32523631 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920921980 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|